Price History

Hover for the daily close. The dotted line marks the period open.

Compare NXTC with… →

NXTC Key Statistics

As of Sep 4, 2026

Trading

Open: $7.79
Previous Close: $7.84
Day's Range: 7.57–8.23
52-Week Range: 1.55–15.74
Volume: 60.60K
Beta: 1.34

Valuation

Market Cap: $35.79M
P/E Ratio: unprofitable
EPS (ttm): −8.26

Financials (FY)

Revenue (FY): $0.00
Net Income (FY): −$55.84M
Profit margin: 0.00%
Shares Outstanding: 4.58M
1-Year Return: +58.30%

Dividend and dates

Avg Volume: 2.16M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

NXTC Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

+183.07%−80.65%−44.95%−76.50%−19.15%−32.37%+53.37%−44.89%

2019*2020202120222023202420252026*

Year	Return
2026 (partial year)	−44.89%
2025	+53.37%
2024	−32.37%
2023	−19.15%
2022	−76.50%
2021	−44.95%
2020	−80.65%
2019 (partial year)	+183.07%

As of September 4, 2026.

NXTC Revenue and Earnings by Fiscal Year

FY ends December

RevenueNet income

2022202320242025

Fiscal year	Revenue	Net income	Net margin
2025	$0.00	−$55.84M	—
2024	$0.00	−$55.65M	—
2023	$0.00	−$62.72M	—
2022	$0.00	−$74.73M	—

Fiscal year	Revenue	Gross profit	Operating income	Net income	Net margin
2025	$0.00	—	−$57.62M	−$55.84M	—
2024	$0.00	—	−$57.21M	−$55.65M	—
2023	$0.00	—	−$67.64M	−$62.72M	—
2022	$0.00	—	−$75.91M	−$74.73M	—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

NXTC Valuation vs Biotechnology Median

Median of 656 stocks

Metric	NXTC	Biotechnology median	vs median
Profit margin	0.00%	0.00%	0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

NextCure Q2 EPS $(2.80) Misses $(1.94) Estimate
Benzinga2026-08-06

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values NextCure, Inc. (NXTC) at $35.79M. The company sits in the Healthcare sector, in the Biotechnology industry. Headcount on file is 40.

NXTC last closed at $7.82 on September 4, 2026. That is −$0.02 (−0.26%) against the previous close. Over the past 52 weeks the price has ranged from $1.55 to $15.74. The latest close sits 404.52% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $0.00. The same year closed with a net loss of $55.84M. The reported profit margin is 0%. Trailing earnings per share are −8.26.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative.

The trailing one-year price return is +58.30%. Across 5 years the annualized return works out at −39.04%. The reported beta is 1.34. Daily returns over the trailing 7 years annualize to a volatility of 149.17%.

Growth & Income

The record shows no dividend for NXTC.

The strongest complete calendar year on file is 2025 at +53.37%; the weakest is 2020 at −80.65%. Of the 6 complete calendar years on file, 1 finished higher. 2026 is still running; the price is −44.89% year to date.

Peer Comparison

NextCure, Inc. (NXTC) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company	Ticker	Market Cap	P/E Ratio
NextCure, Inc.	NXTC	$35.79M	—
Vertex Pharmaceuticals Incorporated	VRTX	$138.42B	32.5
Regeneron Pharmaceuticals, Inc.	REGN	$85.22B	20.5
argenx SE	ARGX	$64.25B	40.1

The Biotechnology industry average P/E ratio is 12.6x. NextCure, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

ARGX

argenx SE

$64.25B

MRNA

Moderna, Inc.

$58.11B

RVMD

Revolution Medicines, Inc.

$45.01B

ONC

BeOne Medicines AG

$40.53B

View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

JNJ

Johnson & Johnson

$663.28B

ABBV

AbbVie Inc.

$453.19B

MRK

Merck & Co., Inc.

$370.89B

UNH

UnitedHealth Group Incorporated

$356.47B

View all Healthcare stocks →

About NextCure, Inc.

NextCure, Inc., a clinical-stage biopharmaceutical company, engages in advancing medicines to treat cancer. The company's product candidate is the LNCB74, a B7-H4 targeted ADC to kill tumors. It also develops NC410, a fusion protein of LAIR-2, that is designed to block immune suppression mediated by LAIR-1; NC525, a novel LAIR-1 antibody that targets acute myeloid leukemia, blast cells, and leukemic stem cells; NC181 a humanized antibody targeting ApoE4 for the treatment of Alzheimer's disease; and NC605 an antibody that targets Siglec-15, as well as chronic bone diseases, such as osteoarthritis and non-union fractures. The company also develop SIM0505, a novel antibody-drug conjugate (ADC) targeting CDH6 (cadherin-6 or K-cadherin) for the treatment of solid tumors. The company was incorporated in 2015 and is headquartered in Baltimore, Maryland.

Visit website →

NextCure, Inc. (NXTC) Stock Analysis